These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 19281600)
1. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600 [TBL] [Abstract][Full Text] [Related]
2. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813 [TBL] [Abstract][Full Text] [Related]
3. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Enggaard TP; Poulsen L; Arendt-Nielsen L; Brøsen K; Ossig J; Sindrup SH Anesth Analg; 2006 Jan; 102(1):146-50. PubMed ID: 16368820 [TBL] [Abstract][Full Text] [Related]
4. The hypoalgesic effect of tramadol in relation to CYP2D6. Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065 [TBL] [Abstract][Full Text] [Related]
5. Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Arendt-Nielsen L; Olesen AE; Staahl C; Menzaghi F; Kell S; Wong GY; Drewes AM Anesthesiology; 2009 Sep; 111(3):616-24. PubMed ID: 19672186 [TBL] [Abstract][Full Text] [Related]
6. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Zwisler ST; Enggaard TP; Noehr-Jensen L; Mikkelsen S; Verstuyft C; Becquemont L; Sindrup SH; Brosen K Fundam Clin Pharmacol; 2010 Aug; 24(4):517-24. PubMed ID: 19845769 [TBL] [Abstract][Full Text] [Related]
7. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Heiskanen T; Olkkola KT; Kalso E Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425 [TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. Staahl C; Upton R; Foster DJ; Christrup LL; Kristensen K; Hansen SH; Arendt-Nielsen L; Drewes AM J Clin Pharmacol; 2008 May; 48(5):619-31. PubMed ID: 18440921 [TBL] [Abstract][Full Text] [Related]
10. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859 [TBL] [Abstract][Full Text] [Related]
13. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129 [TBL] [Abstract][Full Text] [Related]
14. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544 [TBL] [Abstract][Full Text] [Related]
16. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808 [TBL] [Abstract][Full Text] [Related]
17. Specific effect of levetiracetam in experimental human pain models. Enggaard TP; Klitgaard NA; Sindrup SH Eur J Pain; 2006 Apr; 10(3):193-8. PubMed ID: 15946871 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Koltzenburg M; Pokorny R; Gasser UE; Richarz U Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645 [TBL] [Abstract][Full Text] [Related]
19. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Staahl C; Dimcevski G; Andersen SD; Thorsgaard N; Christrup LL; Arendt-Nielsen L; Drewes AM Scand J Gastroenterol; 2007 Mar; 42(3):383-90. PubMed ID: 17354119 [TBL] [Abstract][Full Text] [Related]
20. Oxycodone alters temporal summation but not conditioned pain modulation: preclinical findings and possible relations to mechanisms of opioid analgesia. Suzan E; Midbari A; Treister R; Haddad M; Pud D; Eisenberg E Pain; 2013 Aug; 154(8):1413-8. PubMed ID: 23707271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]